- Conditions
- Mechanically Ventilated and Intubated Subjects
- Interventions
- Dexmedetomidine HCL Injection, Midazolam Injection
- Drug
- Lead sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 75 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 6,882
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- NX-1207, Placebo
- Drug
- Lead sponsor
- Nymox Corporation
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 35
- States / cities
- Laguna Hills, California • San Diego, California • Tarzana, California + 30 more
- Conditions
- Hepatic Insufficiency
- Interventions
- Simufilam
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Lake Forest, California • Miami, Florida • Orlando, Florida
- Conditions
- Chronic Heart Failure
- Interventions
- HeartWare Ventricular Assist Device
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Little Rock, Arkansas • San Diego, California • San Francisco, California + 38 more
- Conditions
- Esophageal Stenosis
- Interventions
- prednisone, placebo
- Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Interventions
- Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 0 Years to 6 Years · Male only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Pegozafermin, Placebo
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
- Conditions
- Acute Gout Flare
- Interventions
- Rilonacept, Indomethacin, Placebo (for Indomethacin), Placebo (for Rilonacept)
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more
- Conditions
- Heart Failure, COPD, Myocardial Infarction, Coronary Artery Bypass Graft, Pneumonia, Total Knee Replacement, Total Hip Replacement, Stroke
- Interventions
- Not listed
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
- Interventions
- Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
- Drug
- Lead sponsor
- Leaf Vertical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
- Conditions
- Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
- Interventions
- Peramivir+SOC, Placebo+SOC
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 60
- States / cities
- La Mesa, California • Long Beach, California • Modesto, California + 49 more
- Conditions
- Cognitive Change
- Interventions
- Neuroblate System
- Device
- Lead sponsor
- Monteris Medical
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 81 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Orlando, Florida • Kansas City, Kansas + 3 more
- Conditions
- Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Procedure · Other · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 895
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
- Conditions
- Child, Intensive Care Unit Acquired Weakness, Critical Illness, Hospital Acquired Pressure Ulcer
- Interventions
- PICU Up!
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Madera, California • Orlando, Florida • Louisville, Kentucky + 8 more
- Conditions
- Healthy
- Interventions
- Lower Body Resistance Exercise, Upper Body Resistance Exercise
- Other
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Chronic Kidney Disease
- Interventions
- Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 44
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
- Conditions
- ALK-positive Advanced NSCLC
- Interventions
- Brigatinib
- Drug
- Lead sponsor
- Ariad Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Orange, California • Whittier, California • Pueblo, Colorado + 7 more
- Conditions
- Renal Insufficiency
- Interventions
- LY3537982
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Breast Cancer
- Interventions
- Olaparib, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 368
- States / cities
- Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more